Covid-19 roundup: Pfizer strikes vaccine deal with New Zealand, as CEO Albert Bourla defends development rush to critics
Pfizer and BioNTech have inked a deal with New Zealand for 1.5 million vaccine doses to be delivered as early as first quarter next year, according to Reuters.
It’s unclear how much the government is paying for the batch, which should be enough to inoculate 750,000 people.
The news comes as Pfizer CEO Albert Bourla continues to push for data to meet regulatory standards for emergency authorization by the end of this month. The candidate is now President Donald Trump’s only hope for a vaccine before the Nov. 3 election, as Moderna has said that the earliest they will be able to file for an EUA is Nov. 25. Reports have emerged that Bourla’s now trying to get his critics on board.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.